Latest Breaking News On - Yvonne naughton - Page 1 : vimarsana.com

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen s First Quarter 2024 Results Conference Call. At this time, all participants are in a listen-only mode.

Compugen Reports First Quarter 2024 Results

Compugen : Reports First Quarter 2024 Results

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF.

Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

FOR IMMEDIATE RELEASE: Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in .

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

/PRNewswire/ Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today.

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

HOLON, Israel, Feb. 20. 2024 /PRNewswire/ Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will.

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ Compugen Ltd.  a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled.